Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy

Author:

Sah Vasu R.1ORCID,Jespersen Henrik23ORCID,Karlsson Joakim4ORCID,Nilsson Lisa M.4ORCID,Bergqvist Mattias5ORCID,Johansson Iva6ORCID,Carneiro Ana7ORCID,Helgadottir Hildur8ORCID,Levin Max26ORCID,Ullenhag Gustav9ORCID,Ståhlberg Anders1011ORCID,Olofsson Bagge Roger11213ORCID,Nilsson Jonas A.14ORCID,Ny Lars26ORCID

Affiliation:

1. 1Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

2. 2Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.

3. 3Department of Oncology, Oslo University Hospital, Oslo, Norway.

4. 4Harry Perkins Institute of Medical Research, University of Western Australia, Perth, Western Australia, Australia.

5. 5Biovica International AB, Uppsala Science Park, Uppsala, Sweden.

6. 6Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden.

7. 7Department of Oncology, Skåne University Hospital, Lund, Sweden.

8. 8Department of Oncology, Karolinska University Hospital, Stockholm, Sweden.

9. 9Department of Radiology, Oncology and Radiation Science, Section of Oncology, Uppsala University, Uppsala, Sweden.

10. 10Department of Laboratory Medicine, Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

11. 11Department of Clinical Genetics and Genomics, Sahlgrenska Center for Cancer Research, Institute of Biomedicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.

12. 12Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

13. 13Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

Abstract

Purpose: Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed. Patients and Methods: We previously reported that patients treated with the PD-1 inhibitor pembrolizumab and the histone deacetylase inhibitor entinostat in the PEMDAC trial, experienced clinical benefits if their tumor originated from iris or was wildtype for BAP1 tumor suppressor gene. Here we present the 2-year follow-up of the patients in the PEMDAC trial and identify additional factors that correlate with response or survival. Results: Durable responses were observed in 4 patients, with additional 8 patients exhibiting a stable disease. The median overall survival was 13.7 months. Grade 3 adverse events were reported in 62% of the patients, but they were all manageable. No fatal toxicity was observed. Activity of thymidine kinase 1 in plasma was higher in patients with stable disease or who progressed on treatment, compared with those with partial response. Chemokines and cytokines were analyzed in plasma. Three chemokines were significantly different when comparing patients with and without response. One of the factors, CCL21, was higher in the plasma of responding patients before treatment initiation but decreased in the same patients upon treatment. In tumors, CCL21 was expressed in areas resembling tertiary lymphoid structures (TLS). High plasma levels of CCL21 and presence of TLS-like regions in the tumor correlated with longer survival. Conclusions: This study provides insight into durable responses in the PEMDAC trial, and describes dynamic changes of chemokines and cytokines in the blood of these patients. Significance: The most significant finding from the 2-year follow-up study of the PEMDAC trial was that high CCL21 levels in blood was associated with response and survival. CCL21 was also expressed in TLS-like regions and presence of these regions was associated with longer survival. These analyses of soluble and tumor markers can inform on predictive biomarkers needing validation and become hypothesis generating for experimental research.

Funder

Cancerfonden

Vetenskapsrådet

Familjen Erling-Perssons Stiftelse

Stiftelsen Jubileumsklinikens Forskningsfond mot Cancer

Lion's Cancer Foundation West

Sjöbergsstiftelsen

Västra Götalandsregionen

VINNOVA

Stiftelsen Assar Gabrielssons Fond

Kirkbride Melanoma Funds at Harry Perkins Institute of Medical Research

Syndax Pharmaceuticals

Merck & Co. | Merck Sharp and Dohme

Publisher

American Association for Cancer Research (AACR)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3